Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Arcutis Biotherapeutics, Inc. - Common stock (NQ:ARQT)

30.37 -0.28 (-0.91%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 1, 2025 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1,576,797
Open	30.24
Bid (Size)	30.35 (100)
Ask (Size)	30.75 (200)
Prev. Close	30.65
Today's Range	29.85 - 30.65
52wk Range	11.13 - 31.27
Shares Outstanding	50,241,789
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Why Shares in Arcutis Biotherapeutics Surged Again This Week ↗

November 21, 2025

The company continues to receive good news from the Food and Drug Administration.

Via The Motley Fool

10 Health Care Stocks With Whale Alerts In Today's Session ↗

November 19, 2025

Via Benzinga

Performance

YTD	+108.6%	+108.6%
1 Month	+22.8%	+22.8%
3 Month	+98.2%	+98.2%
6 Month	+125.3%	+125.3%
1 Year	+144.6%	+144.6%

More News

FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5

November 17, 2025

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Earnings Scheduled For October 28, 2025 ↗

October 28, 2025

Via Benzinga

Peering Into Arcutis Biotherapeutics Inc's Recent Short Interest ↗

November 13, 2025

Via Benzinga

Arcutis Completes Enrollment in INTEGUMENT-INFANT Phase 2 Study Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis

November 13, 2025

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) Combines Strong Trend with High-Growth Momentum ↗

November 10, 2025

Via Chartmill

Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data of ZORYVE® (roflumilast) Foam 0.3% in Individuals with Seborrheic Dermatitis in American Journal of Clinical Dermatology

November 04, 2025

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Mother-Daughter Duo, Tori Spelling and Stella McDermott, Partner With Arcutis Biotherapeutics in the Free to Be Me Campaign, Urging People With Inflammatory Skin Conditions to Speak With Their Healthcare Provider About Long-Term Treatments

October 30, 2025

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Arcutis Launches ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Children Ages 2 to 5

October 30, 2025

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

These stocks are moving in today's session ↗

October 28, 2025

Via Chartmill

Arcutis Q3 2025 Earnings Call Transcript ↗

October 28, 2025

Via The Motley Fool

Top stock movements in today's session. ↗

October 28, 2025

Via Chartmill

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

October 28, 2025

Via Benzinga

Crude Oil Falls Over 2%; PayPal Shares Spike Higher ↗

October 28, 2025

Via Benzinga

Here's Why This Biotherapeutics Company's Stock Surged Higher by 30% Today ↗

October 28, 2025

Via The Motley Fool

Arcutis Tops A Profit-Taking Zone After Smashing Forecasts. But There Was Another Surprise. ↗

October 28, 2025

Via Investor's Business Daily

Traders are paying attention to the gapping stocks in Tuesday's session. ↗

October 28, 2025

Via Chartmill

Wayfair, Qorvo, Celestica, United Parcel Service, Regeneron Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday ↗

October 28, 2025

Via Benzinga

Arcutis Biotherapeutics Inc (NASDAQ:ARQT) Reports Strong Q3 2025 Earnings Beat and Return to Profitability ↗

October 28, 2025

Via Chartmill

Arcutis Outlines Strategy for Driving Sustainable Growth and Announces Third Quarter 2025 Financial Results

October 28, 2025

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Uncovering Potential: Arcutis Biotherapeutics's Earnings Preview ↗

October 27, 2025

Via Benzinga

Arcutis to Present New Quality of Life and Long-Term Data with ZORYVE® (roflumilast) Cream 0.15% and 0.05% for the Treatment of Atopic Dermatitis at the Fall Clinical Dermatology Conference

October 24, 2025

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5

October 06, 2025

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Arcutis Biotherapeutics to Host Virtual Investor Day and Report Third Quarter 2025 Financial Results on October 28, 2025

September 29, 2025

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Arcutis Biotherapeutics, Inc. - Common stock publicly traded?

Yes, Arcutis Biotherapeutics, Inc. - Common stock is publicly traded.

What exchange does Arcutis Biotherapeutics, Inc. - Common stock trade on?

Arcutis Biotherapeutics, Inc. - Common stock trades on the Nasdaq Stock Market

What is the ticker symbol for Arcutis Biotherapeutics, Inc. - Common stock?

The ticker symbol for Arcutis Biotherapeutics, Inc. - Common stock is ARQT on the Nasdaq Stock Market

What is the current price of Arcutis Biotherapeutics, Inc. - Common stock?

The current price of Arcutis Biotherapeutics, Inc. - Common stock is 30.37

When was Arcutis Biotherapeutics, Inc. - Common stock last traded?

The last trade of Arcutis Biotherapeutics, Inc. - Common stock was at 12/01/25 04:00 PM ET

What is the market capitalization of Arcutis Biotherapeutics, Inc. - Common stock?

The market capitalization of Arcutis Biotherapeutics, Inc. - Common stock is 1.53B

How many shares of Arcutis Biotherapeutics, Inc. - Common stock are outstanding?

Arcutis Biotherapeutics, Inc. - Common stock has 2B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.